This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Crispr Therapeutics AG (CRSP) Gets a Buy from Mizuho Securities
In a report released today, from Mizuho Securities maintained a Buy rating on Crispr Therapeutics AG, with a price target of $85.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $75.00 average price target.
Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.46 million and a GAAP net loss of $122.93 million. In comparison, last year the company earned a revenue of $865 thousand and had a GAAP net loss of $136 million
Read More on CRSP:
Disclaimer & DisclosureReport an Issue
- Shareholders Approve New Incentive Plan and Governance Measures
- FDA issues draft guidance to help accelerated cell, gene therapies for patients
- Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
- Crispr Therapeutics price target raised to $56 from $50 at Bernstein
- FDA Commissioner Marty Makary resigns
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
